Details 1 Related Guideline / Approval

Indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

type

FDA Approval

approval date

2021-09-15

settings
settings
Locally advanced
settings
Metastatic
settings
Subsequent line
source

FDA